MET and neoplasm: The 729 diagnostic tumor samples that were evaluated with the smMIP panel showed 788 (likely) pathogenic mutations, including mutations that give access to targeted treatment options (e.g. mutations in EGFR, BRAF, MET, ERBB2, KIT, PDGFRA).